The MHC class II transactivator CIITA induction as a potential new tool to develop anti-tumor vaccines and predict the efficacy of immunotherapy.
- DOI
- 10.1016/j.yexmp.2026.105078
- Published
- 2026 Sep 22
- Container
- Experimental and molecular pathology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.yexmp.2026.105078,
title = {The MHC class II transactivator CIITA induction as a potential new tool to develop anti-tumor vaccines and predict the efficacy of immunotherapy.},
author = {Celesti F},
year = {2026},
journal = {Experimental and molecular pathology},
doi = {10.1016/j.yexmp.2026.105078},
url = {https://doi.org/10.1016/j.yexmp.2026.105078}
}RIS
TY - JOUR TI - The MHC class II transactivator CIITA induction as a potential new tool to develop anti-tumor vaccines and predict the efficacy of immunotherapy. AU - Celesti F PY - 2026 JO - Experimental and molecular pathology DO - 10.1016/j.yexmp.2026.105078 UR - https://doi.org/10.1016/j.yexmp.2026.105078 ER -
APA
F, C. (2026). The MHC class II transactivator CIITA induction as a potential new tool to develop anti-tumor vaccines and predict the efficacy of immunotherapy.. Experimental and molecular pathology. https://doi.org/10.1016/j.yexmp.2026.105078
Source records
- pubmed · retrieved 2026-09-26T12:30:52.906Z